Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new one-year data showing that its investigational oral drug icotrokinra continues to demonstrate high rates of durable skin clearance and …
Johnson & Johnson’s Oral Psoriasis Drug Shows Strong Long-Term Results Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) released new 48-week results from its Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) as a subcutaneous induction and maintenance therapy for …
Johnson & Johnson’s TREMFYA® Shows Sustained One-Year Efficacy in Ulcerative Colitis Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra, an investigational oral therapy for adults with moderately to …
Johnson & Johnson Reports Positive Phase 2b Results for Oral Ulcerative Colitis Therapy Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA® (guselkumab) for children six years and older weighing at least 40 …
FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic Arthritis Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults …
FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 data showing its investigational oral therapy icotrokinra achieved superior skin clearance compared to deucravacitinib in patients with …
Johnson & Johnson’s Oral Psoriasis Drug Shows Superiority in Phase 3 Trials Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration, seeking approval to update the labeling for …
Johnson & Johnson Seeks FDA Nod for TREMFYA® Label Update Following Psoriatic Arthritis Trial Success Read More SPRING HOUSE, PA — Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for icotrokinra, a once-daily oral peptide therapy targeting the …
Johnson & Johnson Seeks FDA Approval for First Oral IL‑23 Inhibitor to Treat Plaque Psoriasis Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the …
Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia Gravis Read More SPRING HOUSE, PA — On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & Johnson’s cutting-edge FcRn-blocking antibody treatment for generalized myasthenia gravis (gMG). …
FDA Approves Johnson & Johnson’s IMAAVY for Generalized Myasthenia Gravis Read More